Satellos Bioscience Inc.
(MENAFN- Baystreet) 11:25 AM EST - Satellos Bioscience Inc. : Announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration, along with parallel regulatory filings in the United Kingdom, Europe, Serbia and Australia, to initiate a Phase 2 clinical trial of SAT-3247 in ambulatory children with Duchenne muscular dystrophy (Duchenne or DMD). Satellos Bioscience Inc.
shares T are trading up $0.02 at $0.65.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Kucoin Partners With Golf Icon Adam Scott As Global Brand Ambassador
- Mediafuse Joins Google For Startups Cloud Program To Scale AI-Driven, Industry-Focused PR Distribution
- Solotto Launches As Solana's First-Ever Community-Powered On-Chain Lottery
- 1Inch Unlocks Access To Tokenized Rwas Via Swap API
- Leverage Shares Launches First 3X Single-Stock Etps On HOOD, HIMS, UNH And Others
- Forex Expo Dubai 2025 Returns October 67 With Exclusive Prize Draw Including Jetour X70 FL
More Story
Comments
No comment